Clinical trial
Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis
NCT00237380 · PTC Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00237380 |
|---|---|
| Title | Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis |
| Official title | A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis |
| Lead sponsor | PTC Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cystic Fibrosis |
| Intervention type | Drug |
| Interventions | Ataluren |
| Enrollment | 24 |
| Start date | Nov 30, 2005 |
| Primary completion | May 31, 2006 |
| Completion | May 31, 2006 |
| First posted | Oct 12, 2005 |
| Last update posted | Jun 11, 2020 |
| Countries | Israel |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: